Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT-2: Butylphthalide + Tenecteplase in Mild Disabling Acute Ischemic Stroke
NCT07369999Phase 3Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Feb 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of butylphthalide in ischemic stroke, sponsored by Xiangya Hospital, Central South University. Started Feb 2026; status: recruiting.
02
Drugs
butylphthalide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07369999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369999.